Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PancVax: DC Vaccine and Chemotherapy for Pancreatic Cancer
NCT02548169Phase 1Terminated
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Aug 2015
- Primary completion
- Apr 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in pancreatic cancer (PC), sponsored by Baylor Scott & White Research Institute. Started Aug 2015; status: terminated.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02548169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548169.